For Patients April 2026

CMEF 2026 in Shanghai: AI in Diagnostics, Robotics, and New Medical Devices Through an Oncologist’s Eyes

In Shanghai I had the chance to visit the China Medical Equipment Fair (CMEF 2026) — one of the largest medical equipment exhibitions in the world, held on April 9–12, 2026 across more than 320,000 m². The exhibition brought together nearly 5,000 brands and companies from more than 20 countries.

The main takeaway: artificial intelligence is no longer a toy for information retrieval. At CMEF it is already embedded in medical devices, diagnostic workflows, MRI, CT, neurotechnology, rehabilitation, and robotic surgery.

For oncology this is not an abstract future. Diagnostics, imaging speed, biopsy accuracy, choice of biopsy site, treatment response assessment, and home-based patient monitoring are all becoming part of a single digital chain.

Event Highlights

At CMEF 2026 the central themes were AI in medicine, robotics, brain-computer interfaces, medical imaging, and international cooperation. Organizers highlighted a separate Future Tech Arena: brain-computer interface, embodied intelligence, and university-developed solutions.
Manufacturers showed “AI + medical device” combinations: MRI with accelerated reconstruction, CT with automated analysis, diagnostic decision support, exoskeletons, surgical robots, and home monitoring devices.
Philips announced that its SmartSpeed AI technology for MRI can accelerate scanning up to 3× and improve resolution by up to 65% compared with traditional approaches.
In March 2026, China’s NMPA approved an implantable brain-computer interface system to restore hand motion in patients with tetraplegia after cervical spinal cord injury.
Wandong Medical presented a 7T MRI-based agent for early diagnosis of Alzheimer’s disease, built on MRI data from nearly 50,000 healthy Chinese adults. The company claims early detection can be shifted forward by 3–5 years.
Also shown: transbronchial flexible robots for diagnosing and treating early lung cancer, robotic systems for biopsy of lung lesions, single-port surgical robots, and home-monitoring solutions for chronic disease.

Why This Matters for Oncology

Precision diagnostics are critically important for oncology patients. The outcome of treatment is often determined not only by the drug but by how accurately the biopsy was performed, whether enough material was obtained for morphology and molecular testing, whether tumor extent was correctly assessed, and whether serial imaging is truly comparable.

This is why transbronchial robotic systems can reshape the pathway for patients with suspected lung cancer: reaching small lesions more precisely, obtaining tissue for histology and biomarkers, and reducing the number of non-informative procedures. AI in CT, MRI, and PET-CT is already helping to triage studies, accelerate reconstruction, reduce repeat scans, detect lesions, and standardize reports — which means less waiting time, less uncertainty, and better patient routing.

Limitations: What to Keep in Mind

A medical equipment exhibition does not equal immediate clinical adoption. At CMEF you can see technologies that look very convincing — even beautiful — but this does not mean they have already become a standard of diagnostics or treatment.

AI algorithms require independent validation. It matters which data they were trained on, which population they were validated for, which endpoints were evaluated, how often they err, who is responsible for the final conclusion, and how the algorithm is integrated into clinical workflow.

Robotic surgery and robotic biopsy should not be seen as universally the better option. There are situations where the technology genuinely adds value. There are situations where the standard method is simpler, more available, safer, and no worse by result. The decision depends on the diagnosis, tumor location, stage, patient condition, and the team’s experience.

Moreover, foreign regulatory approval — including China’s NMPA — does not mean the technology is available in Russia. If a patient sees news of a foreign innovation, one of the first questions (alongside efficacy) should be: is it actually accessible?

As a physician and researcher, I view these data with great interest. CMEF clearly shows the direction of development and broadens one’s perspective. But between an exhibition booth and routine clinical practice there is always a distance — sometimes a gulf.

New technologies, AI, and robotics should not replace clinical thinking. They only amplify good medicine and those centers of competence where the right questions are asked, competent physicians work, a clear patient pathway is mapped, and proven technology is used. For a patient, the best approach is not to search for the most modern machine but to work together with their doctor to determine which diagnostics and treatment are truly needed in their specific situation.

Conclusion

CMEF 2026 demonstrated that AI and robotics are becoming integral parts of modern medicine. But the clinical value of a technology is determined not by its novelty but by how well it is integrated into a patient’s pathway and into the hands of a team that knows how to work with it.

When a Second Opinion Is Especially Helpful

when there are ambiguous CT, MRI, or PET-CT results;
when a repeat biopsy or additional molecular testing is under discussion;
when a clinic offers a “robotic” or “AI-supported” procedure and the patient wants to understand whether this is truly the best option for their case;
when standard options are limited and technologies available only abroad are being considered;
when you need to understand which current diagnostic approaches apply to your situation and which do not yet change the strategy.

Frequently Asked Questions

Can AI make a diagnosis instead of a doctor?

Not yet. AI can help physicians speed up image processing, highlight suspicious zones, triage studies, and standardize parts of the workflow. But in oncology, a diagnosis is made based on clinical findings, morphology, imaging, biomarkers, and the decision of a medical team.

Should I look for a clinic that has a robot?

Not always — and more often, no. Robotic technology matters only when it solves a specific clinical task better or more safely than the standard approach. Moreover, an experienced team using a standard method proven in practice delivers better results than a new technology without sufficient operational experience.

Are the technologies shown at CMEF 2026 available in Russia?

Some technologies may have local analogues or certain components available, some are not yet available, and some may only be available in the context of foreign practice or research. A foreign exhibition or foreign registration does not equal availability in Russia.

Can exhibition data be used to choose treatment?

Exhibition data are useful for understanding the direction of medical development, primarily for medical experts and managers. They do not replace clinical guidelines or an individual consultation. Choosing treatment requires diagnosis, stage, morphology, biomarkers, patient condition, and verified medical data.